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Background: Cystic fibrosis (CF) is characterized by an excessive inflammatory response in epithelial cells and macrophages. In CF mice,
lung inflammation can be abrogated by oral treatment with docosahexaenoic acid (DHA). Since PPARs and LXRs are important regulators of
inflammation and fatty acid metabolism in macrophages, we hypothesized that these pathways are dysregulated in CF macrophages and are
corrected with DHA treatment.
Methods: Peritoneal macrophages were obtained from wild type and cftr−/− mice. LPS induced cytokine secretion and NFκB activity were
analyzed with and without oral DHA treatment. The expression and activity of PPARα,γ, δ and LXRα were analyzed by RT-PCR and EMSA.
Results: LPS induced TNFα and IL-6 secretion and NFκB p65 activity were increased in CF macrophages. This was associated with low
basal PPARγ expression and attenuated LPS induced induction of PPARδ, LXRα and ABCA1. DHA pretreatment in vivo decreased TNFα
secretion and p65 activity, and increased PPARα and γ expression and function. The effects of DHA could be reproduced by PPAR agonists
and blocked by a PPARα antagonist.
Conclusion: Impaired regulation of nuclear receptors may contribute to the abnormal LPS induced signaling in CF macrophages and is
reversed by DHA.
© 2007 Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.Keywords: Cystic fibrosis mice; Nuclear receptors; Macrophages; Inflammation; Docosahexaenoic acid; CytokinesCystic fibrosis (CF) is a genetic disease caused by
dysfunction of the cystic fibrosis transmembrane conduc-
tance regulator (CFTR) protein. This defect is associated
with a progressive decrease in lung function caused by
chronic bacterial infection and inflammation. Normally, a
persistence of bacterial leads to a switch from neutrophils to
a less damaging chronic inflammatory response, involving
macrophages and lymphocytes. However, in CF that
modulation never takes place and the airway inflammation
is characterized by persistent neutrophilic infiltration that☆ Data from this manuscript were presented at the North American Cystic
fibrosis Conference 2004 in Anaheim, CA and 2005 in Baltimore, MD.
⁎ Corresponding author. 330 Brookline Ave, Dana 501, Boston, MA,
02215, United States. Tel.: +1 617 667 5576; fax: +1 617 667 0536.
E-mail address: sfreedma@bidmc.harvard.edu (S.D. Freedman).
1569-1993/$ - see front matter © 2007 Published by Elsevier B.V. on behalf of E
doi:10.1016/j.jcf.2007.05.004does not manage to clear the infection. A contributing factor
for this appears to be a defective clearance of apoptotic cells
by macrophages, a process that involves CFTR [1].
Increasing evidence suggests that mutations in the CFTR
gene are connected with dysregulation of the innate immune
response in both CFTR expressing epithelial cells and
monocytes/macrophages. Tirouvanziam et al. [2] showed in
a model of naive human airways using tracheal grafts that CF
airways are in a proinflammatory state in the absence of
infection with increased numbers of subepithelial leukocytes
and increased IL-8 levels. The same phenomenon is seen in
cftr−/− mice. Cftr−/− mice raised in pathogen free conditions
exhibit more lymphocytes in their airways than wild type
(WT) mice [3]. Using microarray analysis, Xu et al.
compared mRNA expression in lung tissue from cftr+/+
and cftr−/− mice without any infection. Genes involved in the
inflammatory response were overly represented among theuropean Cystic Fibrosis Society.
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and CSF-1 receptor as well as genes of the calgranulin family
[4]. The calgranulins are calcium-binding proteins that are
primarily expressed by monocytes and macrophages in re-
sponse to TNFα, interferon γ, and IL-1β.
Altered cytokine production has been described in human
CF airway epithelial cells and gland cells aswell as neutrophils,
lymphocytes, monocytes andmacrophages [5–8]. Cftr−/−mice
do not exhibit spontaneous lung inflammation, but they are
more susceptible to Pseudomonas aeruginosa induced lung
inflammation [9,10]. Following aerosolized P. aeruginosa
LPS exposure, cftr−/− mice display increased levels of TNF-α,
MIP-2, and KC in their bronchoalveolar lavage (BAL) fluid
compared toWTmice [9]. These reports indicate that immune
cell infiltration and excessive cytokine production is linked to
an inherent effect of dysfunctional CFTR.
One possible cause for the predilection for inflammation
in CF is alterations in phospholipid-bound fatty acids within
CFTR regulated cells. It has been shown that arachidonic
acid levels are increased and docosahexaenoic acid (DHA)
levels decreased in CF affected organs in transgenic mouse
models [11] as well as in humans with CF [12]. Correction of
this fatty acid defect with high doses of orally administered
DHA reversed the pathologic changes including the
excessive inflammatory response in the lungs [8] and bile
ducts [13] of these cftr−/− mice.
How CFTR dysfunction leads to the fatty acid abnor-
malities is unknown as well as the mechanism of action by
which DHA ameliorates the inflammatory reponse. Perox-
isomal proliferator activated receptors (PPAR) and liver X
receptors (LXR) could provide the link between these pro-
cesses. These nuclear receptors are well known regulators
of fatty acid and cholesterol metabolism. More recently
their role as inflammatory regulators has emerged [14].
PPAR and LXR activation inhibits pro-inflammatory cyto-
kine expression both in vitro and in vivo and are important
for resolution of inflammation [15–18] through interactions
with both NFκB and activator protein 1 signaling pathways
[14].
There are three forms of PPARs, α, γ and δ (also called β)
with tissue specific expression. All PPAR isoforms are
expressed in immune cells such as monocytes/macrophages
and B and T lymphocytes [19–22]. PPARα−/− mice exhibit
increased lung inflammation and cytokine secretion after
challenge in a murine asthma model compared to WT mice
[23]. Activation of PPARγ in alveolar macrophages enhances
phagocytosis of apoptotic neutrophils [24] and suppression of
neutrophil chemotaxis, essential roles for resolution of in-
flammation. LXR−/− mice are susceptible to infection with
bacterial strains such as Listeria which play an important
pathogenic role intracellularly [25].
PPARs are activated by polyunsaturated fatty acids such
as DHA as well as fatty acid metabolites that are produced
during inflammatory responses. For example, PPARα is
activated by leukotriene B4 and 8S-hydroxyeicosatetraenoic
acid (HETE) while 15-HETE and 15-deoxy-D12,14-prosta-glandin J2 (15dPGJ2) are PPARγ ligands. Thus, inflamma-
torymediators activate PPAR's thereby initiating the resolution
phase of inflammation [26].
LXRα is expressed primarily in macrophages with lower
levels in liver, intestine and adipose tissue [27–29], whereas
LXRβ is widely expressed [29]. LXRα and LXRβ are rec-
ognized for their importance in cholesterol metabolism and
regulation of inflammation in macrophages. LXR activates
transcription of members of the ABC superfamily of mem-
brane transporters, including ABCA1 [30]. Although oxyster-
ols are the classical activators of LXR [31,32], recent studies
indicate that LXR, by responding to fatty acids, also are an
general regulators of fatty acid metabolism [33,34].
Although there is increasing evidence that macrophages
are involved in the defective immune regulation in CF, most
research to date has been focusing on the response of airway
epithelial cells. In this study we focused on the LPS induced
immune response in CF macrophages and the effect of the n-
3 fatty acid DHA. Since PPARs and LXRs are important in
the regulation of inflammation and fatty acid metabolism in
macrophages and PPARγ expression is decreased in tissues
from cftr−/− mice, we hypothesized that 1) CF macrophages
are primed for inflammation due to dysfunctional expression
of nuclear transcription factors and 2) DHA and other
specific PPAR agonists act on macrophages to ameliorate the
CF associated inflammation. For this study we chose to use
peritioneal macrophages since they are more readily ob-
tained in sufficient numbers compared to lung macrophages
from cftr−/− mice.
1. Materials and methods
1.1. Materials
IGEPAL, Protease Inhibitor Coctail (#P8340) was ob-
tained from Sigma-Aldrich, St Louis, MO; thioglycollate
broth was obtained from Becton Dickinson, Sparks, MD.
1.2. Mouse colony
Experiments were carried out under protocols approved
by the Beth Israel Deaconess Medical Center Animal Care
Committee. The mice were housed in the animal facility at
Beth Israel Deaconess Medical Center in a room that was
controlled for temperature (20–22 °C), humidity (30–70%)
and light (light 6AM to 8PM). Exon 10 cftr−/− mice from our
established breeding colony and their WT littermates were
used for the experiments. Tail-clip samples of 14 days old
mice were used for genotype analysis. The mice were
weened at 23 days of age. All mice were maintained on
Peptamen (Nestle Clinical Nutrition, Deerfield, IL) and
water. One week before experiment WT littermates were put
on Peptamen and water. For studies determining the effect of
in vivo pretreatment of DHA, cftr−/− or WT mice were fed
40 mg/day of DHA (Neuromins, Sudbury, MA) emulsified
in Peptamen for 10 days.
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Macrophages were induced by IP injection of 2 ml
thioglycollate broth (3.95 g/100 ml). After 4 days the mice
were euthanized with CO2. Macrophages were obtained by
peritoneal lavage with 10 ml of chilled PBS. Macrophages
were centrifuged and the pellet used for protein extraction,
fatty acid extraction or RNA extraction, or macrophages
were plated for LPS stimulation.
1.4. Elisa
Peritoneal macrophages were obtained as described.
Harvested macrophages were plated (0.5 million cells/well
in 12 well plates) in RPMI medium with 10% serum. After
40 min attached cells were, washed and incubated for 16 h
with media alone (control and DHA in vivo studies) or with
DHA, EPA, 22:5 n-3, 24:6 n-3, 18:2 n-6 (all 5 μM),
Wy14643 (50 μM, Biomol, Plymouth Meeting, PA),
rosiglitazone (10 μM, Cayman, Ann Arbor, MI), MK-886
(10 mM, Cayman) or BADGE (1–10 mM, Cayman). Cells
were then stimulated with 0–10000 ng/ml LPS for 4.5 h.
TNFα and IL-6 secretion were measured in the supernatant
by ELISA according to the instructions from the manufac-
turer (R&D systems, Minneapolis, MN).
1.5. NFκB activity assay
Peritoneal macrophages were obtained as described and
seeded onto 24 well plates (1.5 million/well) in RPMI
medium with 10% serum. After attachment the medium was
changed and the cells rested for 16 h. Cells were then
stimulated with 100 ng/ml LPS for 30 min and after two
washes lysed with complete lysis buffer (Active motif,
Carlsbad, CA). P65, p50, RelB, c-Rel, and p52 activity were
measured with a kit from Active motif according to
instructions from the manufacturer. 9 μg protein was added
per well.Fig. 1. Analyses of cytokine secretion in CF and WT macrophages. Peritoneal ma
4.5 h with various concentrations of LPS. TNFα (A) and IL-6 (B) secretion into the m
oral DHA 40 mg/day. n=6. ⁎ pb0.05 statistical difference compared with WT. †1.6. Fatty acid analysis
Peritoneal macrophages were resuspended in 0.5 ml PBS.
After adding heptadecaenoic acid as internal standard the
samples were extracted in 3 ml Chloroform-Methanol 2:1 in
glass tubes. After centrifugation at 800 ×g for 3 min the lower
phase was transferred to a new tube and dried under nitrogen
gas. 0.5 ml methanolic base (Sigma-Aldrich) was added, the
sample was vortexed and incubated at 100 °C for 3 min.
0.5 ml Borontrifluoride solution was added and the samples
vortexed and incubated for 1 min at 100 °C. After adding
0.5 ml hexane (Sigma, HPLC pure) the samples were
vortexed and incubated at 100 °C for 1 min. 6.5 ml saturated
NaCl was added and the samples centrifuged for 3 min at
800 ×g. The upper phase was transferred to a new tube and
fatty acids were analyzed by gas chromatography/mass
spectrometry (GC/MS). GC/MS analysis was performed on a
Hewlett-Packard Series II 5890 gas chromatograph coupled
to an HP-5971 mass spectrometer equipped with a Supelco-
wax SP-10 capillary column. Fatty acids were quantified
comparing areas of unknown FAMEs to that of a fixed
concentration of 17:0 internal standard.
1.7. Real-time PCR
Macrophages were seeded to 6-well plates is RPMI
medium. After 2 h of attachment medium was changed to
R10 (RPMI medium with 10% FCS) and cells rested over
night. Cells were then stimulated with 100 ng/ml LPS
(Escherichia coli O55:B5 LPS; Sigma-Aldrich, St. Louis,
MO) and RNA was extracted after 8 h (LPS and control),
16 h and 24 h using STAT-60 (Tel-Test, Friendswood, TX).
For analysis of nuclear nuclear receptor expression after
DHA treatment in vivo, RNA was extracted from the
peritoneal macrophages without previous plating. RNA was
then converted to cDNA using Multiscribe Reverse Tran-
scriptase and random primers (Applied Biosystems). Quan-
titative PCR was performed in a 7500 Real time PCR systemcrophages were plated, rested over night and the next day and incubated for
edia was assayed by ELISA. Some animals were pretreated for 10 days with
pb0.05 statistical difference compared with cftr−/− mice.
Fig. 2. Analyses of NFκB activity in WT and CF macrophages. Peritoneal macrophages were plated, rested over night and then stimulated with 100 ng/ml LPS
for 30 min. A. The cells were lysed and 9 mg/well protein were analyzed for NFκB activity B. p65 activity in plated macrophages after LPS stimulation with and
without oral administration of DHA for 10 days (40 mg/day). ⁎ p≤0.05, ⁎⁎ pb0.01, ⁎⁎⁎ pb0.001 comparing to control without LPS stimulation unless
otherwise indicated; n=6.
Table 1















22:6 (DHA) 2.4±0.3 2.9±0.3
Fatty acids were extracted and methylated from peritoneal macrophages and
analyzed by GC/MS. Heptadecaenoic acid was used as internal standard.
Data are expressed in mol% of total fatty acids (mean ±SEM) and are
representative of at least 7 mice per group. ⁎ pb0.05.
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mix kits (Applied Biosystems) according to the manufac-
turer's instructions for PPARα, δ, RXRα, LXRα, Acyl CoA-
oxidase, CD36, ABCA1 and acidic ribosomal phosphopro-
tein (RB23). PPARγ1 FAM-labeled TaqMan probes were
provided by Integrated DNA Technologies (Coralville,
Iowa). Secquence for PPARγ1 was exon 2 forward primer:
50-TCA CAA GAG CTG ACC CAA TGG T-30, exon 2
reverse primer: 50-ATA ATA AGG TGG AGA TGC AGG
TTC TAC-30, Probe: 50-FAM-CTG AAG CTC CAA GAA
TAC CAA AGT GCG ATC-TAMRA-30. Results were nor-
malized to RB23 mRNA levels. All samples were analyzed
in duplicates.
1.8. Protein extraction
Nuclear fractions were prepared according to a protocol
from Sigma (NXTRACT Technical bulletin No. MB625). The
cell pellet was resuspended in 100 μL isotonic lysis buffer
containing 1 μL 0.1 M DTT and protease inhibitor coctail,
incubated on ice for 15 min. IGEPAL was then added (final
concentration 0.5%) and the samples vortexed for 10 s
followed by centrifugation at 11000 g for 30 s. The super-
natant (cytosolic fraction) was removed and 20–50 μl of
extraction buffer was added to the pellet. The samples were
vortexed at 4 °C for 15–30 min and then centrifuged at
21000 g for 5 min. The supernatant (nuclear fraction) was
transferred to a new tube. Protein concentration was deter-
mined by Bradford protein assay (Bio-Rad, Hercules, CA).
1.9. EMSA
Electrophoretic mobility shift assay (EMSA) was per-
formed as previously described (Tzameli et al., 2000) with
some modifications. Protein samples were mixed with EMSAbuffer (10 mM Tris HCl pH 8, 0.05% NP40, 1 mM DTT,
40mMKCl, 6%glycerol) and dI/dT 3μg/ml. Double-stranded
oligonucleotides (Invitrogen, San Diego, CA) containing a
perfect consensus DR1 motif (synthetic PPAR response
element-PPRE)(5′-AGC TAC GTG ACC TTT GAC CTG
GT-3) were end-labeled with [γ-32P] ATP (New England
Nuclear, Boston, MA). 50 kCPM of the probe was incubated
with 5 μg of nuclear extracts in EMSA buffer, for 20 min at
room temperature. For supershift, a PPARα antibody (Santa
Cruz Biotechnology, Santa Cruz, CA) were incubated with the
nuclear extracts overnight, after addition of the probe.
Competition for specific binding was performed by adding
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prior to the addition of the probe. The complexes were
resolved on a 5% TBE gel (Bio-Rad, Hercules, CA) and
visualized by autoradiography overnight. Densitometric
quantitation was performed using Quantityone software
(Applied Biosystems).
1.10. Statistical analysis
The results are expressed as mean±SEM. Data were
analyzed by Student's t-test.
2. Results
2.1. CF macrophages display increased LPS induced
cytokine secretion and altered NFκB induction
In order to determine whether there is an intrinsic abnor-
mality in immune function in CF macrophages, we initially
tested whether LPS-induced cytokine secretion is increased in
CF macrophages from cftr−/− mice compared to WT animals.Fig. 3. Nuclear receptor mRNA expression by RT-PCR as a function of LPS stimu
LPS (time 0) or with 100 nM LPS for 8 h, 16 h, and 24 h. mRNA expression w
C. PPARδ; D. RXRα; E. LXR; F. ABCA1. ⁎ pb0.05 comparing WT and CF. †
compared with CF control. Figures are representative of three different experimenLPS stimulation of CF peritoneal macrophages in vitro led to
an increase in both TNFα (3.1 fold) and IL-6 (2.3 fold) secre-
tion compared to that seen fromWTmacrophages (Fig. 1A,B).
Pretreatment of cftr−/−micewith oralDHA for 7 days decreased
LPS induced TNFα secretion from peritoneal macrophages by
43% (pb0.05), but had no effect on IL-6 secretion.
In order to assess NFκB activity in the peritoneal
macrophages, binding of the NFκB proteins p65, p50, RelB
c-Rel and p52 to the NFκB consensus site was analyzed and
are shown in Fig. 2A. There were no significant differences
in the expression of any of the NFκB proteins at base line
between cftr−/− and WT mice. Stimulating the macrophages
with LPS led to a significant increase of p65 and p50 in both
WT and CF cells. However, the p65 activity was higher in
CF macrophages than in WT macrophages after LPS
stimulation. LPS stimulation led to a small but significant
increase of RelB and c-Rel in WT but not in CF mac-
rophages. Treatment of the mice with DHA reduced p65
activity in both WT and CF macrophages after LPS
(Fig. 2B). There was no effect on the other NFκB proteins
(data not shown).lation and CFTR function. Macrophages were plated and stimulated with no
as assessed by RT-PCR and normalized to RB23. A. PPARα; B. PPARγ;
pb0.05, †† pb0.01, ††† pb0.001 compared with WT control. ‡ pb0.05
ts, n≥6.
Fig. 4. PPAR activity inWTand CFmacrophages by EMSAwith and without
DHA treatment. A. EMSAwas performed on nuclear fractions from WT and
CFmacrophage samples. 5 μg protein was loaded per well. PPRE binding was
decreased in CF macrophages compared to WT. The results are representative
of three separate experiments. B. Quantification of PPRE binding in WT and
CF macrophages. The PPAR/RXR band from three separate experiments was
quantitated by densitometric scanning. ⁎⁎⁎ pb0.001 C. Effect of oral
administration of DHA on PPARα induction in CF macrophages. WT and
cftr−/− mice were fed peptamen or peptamen containing DHA 40 mg/day for
10 days. Representative results are shown from two WTand three cftr−/−mice
on DHA as well as one CF control mouse on no DHA. 5 μg of nuclear protein
was loaded per well. PPARα antibody and DHA pretreatment was used as
indicated in the figure.
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arachidonic acid or DHA levels
Since CF tissues have an altered fatty acid profile with low
DHA levels and high levels of the proinflammatory omega-6
fatty acid arachidonic acid, we examined whether similar
fatty acid changes, which could explain the increased
cytokine secretion, are present in CF macrophages. The
fatty acid content in peritoneal macrophages from WT and
cftr−/− mice was analyzed by GC/MS. We found no
differences in arachidonic acid or docosahexaenoic acid
levels, or in any other major fatty acids (Table 1). However
there was a significant increase in 22:5 n-6, the final fatty acid
in the n-6 pathway downstream of arachidonic acid, in CF
peritoneal macrophages.
2.3. Nuclear transcription factor mRNA expression is
altered in CF compared to WT peritoneal macrophages as
a function of LPS exposure
Since expression of the nuclear transcription factor
PPARγ is low in ileum and colon of cftr−/− mice [42] and
diminished levels in CF macrophages would potentially lead
to a proinflammatory state, PPAR, RXR and LXR expression
was analyzed in CF macrophages. mRNA levels were
measured by quantitative PCR at 0, 8, 16 and 24 h after
100 ng/ml LPS stimulation in vitro. The expression in WT
macrophages is as follows: There were no significant changes
in PPARα expression as a function of LPS stimulation
(Fig. 3A). PPARγ expression decreased by 97% in WT
macrophages within 8 h of LPS stimulation and remained at
this level for 24 h (Fig. 3B). PPARδ, LXRα and ABCA1, on
the other hand, were increased by LPS exposure in WT
macrophages. PPARδ increased 3-fold after 8 h of LPS
exposure (Fig. 3C) and LXRα increase 2.5 fold after 16 h of
LPS exposure (Fig. 3E). Expression of ABCA1, a target gene
of LXR activation increased 4-fold after 8 h and was further
increased to 5.5-fold of control levels after 24 h (Fig. 3F).
There was no significant change in RXR expression after LPS
exposure (Fig. 3D). The results of LPS exposure of WT
macrophages presented here are consistent with the results in
a recent study by Barish et al. [35].
The expression of nuclear transcription factors in CF
macrophages was then examined. There was no difference in
PPARα expression comparing WT and CF macrophages.
Basal expression of PPARγ in CF macrophages was 25% of
the levels seen in WT macrophages, with the response to
LPS being similar to WT macrophages. LPS induced
PPARδ expression was attenuated at all time points
following LPS exposure in CF macrophages compared to
WT macrophages (Fig. 3C). RXRα was significantly lower
in CF macrophages only at the 16 h time point although the
trend was there at all time points (Fig. 3D). The increase in
the expression of both LXRα and its target gene ABCA1
were attenuated with LPS exposure compare to WT
macrophages (Fig. 3E,F). Taken together, these data indicatethat in CF macrophages, basal expression of PPARγ is
decreased and following LPS stimulation, there is an
attenuation in the increase in PPARδ, LXRα and ABCA1.
2.4. PPAR DNA binding is decreased in CF macrophages
and is restored by DHA
Given the alteration in PPARγ mRNA expression by
quantitative PCR, we examined whether this was linked with
decreased function. PPAR function in macrophages was tested
by assessing binding to the PPAR response element (PPRE)
in an EMSA assay. Fig. 4A shows the PPRE binding in WT
and CF macrophages. Competition for specific binding was
performed by adding an excess of unlabeled oligonucleotide to
the reaction, 30 min prior to the addition of the probe. This
completely inhibited the binding to labeled PPRE in the WT
sample (data not shown) demonstrating the specificity of
this band. Binding to PPRE was significantly decreased in
CF macrophages compared to WT. Fig. 4B shows the quan-
tification of the PPAR/RXR band from WT and CF macro-
phages from three different experiments. This demonstrates
74 C. Andersson et al. / Journal of Cystic Fibrosis 7 (2008) 68–78a statistically significant decrease in PPAR binding in the CF
compared to WT macrophages.
Since DHA is a known PPARα ligand, we tested whether
DHA given orally to the mice increased PPARα activity in
macrophages. Shown in Fig. 4C are the results from two WT
and 3 cftr−/− mice to show the variability in PPRE binding
fed with oral DHA for 10 days. The results from one cftr−/−Fig. 5. Effect of oral DHA administration in CF and WT mice on mRNA expre
peritoneal macrophages from mice with or without pretreatment with oral DHA. W
B Acyl-CoA-Oxidase; C. PPARγ; D. CD36; E. PPARδ; F. RXRα; G. LXRα; H. A
Results are representative of 2 separate experiments, n=6 for each group.mouse not given DHA is shown in lane 11 and is similar to
the results seen in Fig. 4A. Macrophages from WT mice fed
DHA showed prominent PPRE binding. Incubation with a
PPARα antibody resulted in a significant reduction in the
intensity of the PPAR/RXR band. Cftr−/− mice fed for
10 days with DHA demonstrated increased PPRE binding in
the CF macrophage samples (lanes 5–10) compared tossion of nuclear receptors and their target genes. RNA was extracted from
T and CF macrophages were analyzed for mRNA expression of: A. PPARα;
BCA1. All data were normalized to RB23 expression. ⁎ pb0.05, ⁎⁎ pb0.01.
Fig. 6. Effect of DHA and PPAR agonists on cytokine secretion in vitro. Peritoneal macrophages were plated and incubated with media alone (CON) or
containing DHA (5 μM), Rosiglitazone (ROSI; 10 μM ), or WY14643 (WY; 50 μM) for 16 h. Cells were then stimulated with 100 ng/ml LPS for 4 h and TNFα
and IL-6 were assayed in the media by ELISAwith control values normalized to 100%. ⁎ pb0.05, ⁎⁎ pb0.01, ⁎⁎⁎ pb0.001 statistical difference compared with
control. Data shown are the means±SEM from 3 different experiments.
Fig. 7. Effect of the PPARα inhibitor MK-886 and other fatty acids on
cytokine secretion in vitro. Peritoneal macrophages were plated and
incubated with media alone or containing DHA (5 μM), DHA+MK-886
(10 μM), MK-886, eicosapentaenoic acid (EPA; 5 μM), 22:5 n-3 (5 μM),
24:6 n-3 (5 uM) or linoleic acid (LA; 5 μM). Results are representative of 2
separate experiments, n=6 for each group. ⁎ pb0.05, ⁎⁎ pb0.01 comparing
to control, † pb0.05, †† pb0.01 comparing to DHA.
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RXR band was significantly decreased after incubation with
the PPARα antibody.
2.5. DHA increases expression of nuclear receptors
selectively in CF macrophages
We also studied the effect of DHA treatment on the
mRNA expression of PPARs and LXRα as well as genes
regulated by these transcription factors, as an assessment of
their activity (Fig. 5). DHA pretreatment did not have any
effect on the transcription factors tested in the WT mice.
However, in the CF macrophages expression of both
PPARα and PPARγ as well as of their target genes, acyl-
CoA-oxidase and CD36 respectively, were upregulated by
DHA pretreatment in vivo. Also RXRα was increased in the
CF macrophages after DHA treatment. DHA treatment did
not increase expression of PPARδ, LXRα or the LXRα
regulated gene ABCA1.
2.6. DHA and specific PPAR agonists decrease LPS induced
cytokine secretion in vitro
In order to determine the role of PPARα and γ in the CF
associated increase in TNFα and IL-6 secretion from CF
macrophages, the effects of in vitro treatment with DHA and
other PPAR agonists on LPS induced TNFα and IL-6 secretion
were examined (Fig. 6). DHA in vitro decreased
TNFα secretion in both CF and WT macrophages by 22%
and 20%, respectively. No differences were seen with IL-6 in
CF macrophages compared to control, consistent with the data
in vivo shown in Fig. 1B. However, a statistically significant
decrease of IL-6 was seen in WT macrophages in response to
DHA. Rosiglitazone, a PPARγ agonist, decreased TNFα
secretion by 33% (pb0.001) in CFmacrophageswith no effect
on IL-6 secretion. Wy14643, a PPARα agonist, decreased
TNFα secretion in CF macrophages by 16% (pb0.001) with
similar results seen in WTmacrophages. WY14643 decreased
IL-6 by 16% (pb0.05) in CF macrophages but not in WT.
Taken together, these data demonstrate that DHA as well asPPARα and γ agonists, attenuate TNFα secretion from CF
macrophages with less significant effects on IL-6 secretion.
2.7. The effect of DHA on TNFα secretion is blocked by a
PPARα antagonist
We then studied whether the effect of DHA on TNFα
secretion could be inhibited by PPAR antagonists. The 5-
lipoxygenase activating protein inhibitor MK886 was recently
found to inhibit PPARα with minimal effects on PPARγ and
PPARδ [36]. MK886 significantly inhibited the effect of DHA
on TNFα secretion (Fig. 7).We also used the PPARγ inhibitor
BADGE, but this substance was toxic to the cells.
2.8. The effect of DHA on TNFα secretion is not reproduced
by other n-3 fatty acids
We also examined the specificity of DHA by comparing
it to other fatty acids (Fig. 7). For comparison we used
76 C. Andersson et al. / Journal of Cystic Fibrosis 7 (2008) 68–78three other polyunsaturated omega-3 fatty acids 20:5 (EPA),
22:5 and 24:6 as well as the essential n-6 fatty acid 18:2
(linoleic acid).
DHA was the only n-3 fatty acid that significantly de-
creased TNFα secretion (Fig. 7). Linoleic acid decreased
TNF secretion in CF macrophages but not WT.
3. Discussion
This study shows that the innate immune response in
macrophages from cftr−/− mice, as measured by LPS stim-
ulated TNFα and IL-6 secretion, is abnormal compared to
WT macrophages. These results are consistent with studies
that have demonstrated an abnormal LPS chemokine
response in human monocytes from CF patients [7,37] and
in bone marrow derived macrophages from cystic fibrosis
mice [8]. CFTR is expressed at low levels in human mac-
rophages [38]. This was confirmed in mouse macrophages
by Thomas et al. [8] and provides support for a direct relation
between CFTR and this aspect of the immune response in
macrophages.
In order to understand the mechanism for this augmented
LPS induced response in CF macrophages, an analysis of the
five NFκB proteins in peritoneal macrophages without and
with stimulation with LPS was performed. LPS stimulation
is known to induce p65/p50 heterodimers [39,40] that can
activate both TNFα [41] and IL-6 [42] expression in
macrophages. There was increased activity of both p65 and
p50 after LPS stimulation, with a higher activity of p65 in CF
cells compared to WT. Hence it is likely that increased p65/
p50 binding is responsible for the increase in cytokine
secretion from CF macrophages. Increased p65 activity has
previously been shown in CF airway cells [43].
DHA treatment in vivo decreased TNFα but not IL-6
secretion in CF mice. Of the NFκB proteins only p65 was
significantly altered by DHA treatment. This is in agreement
with previous studies showing decreased p65 activity in LPS
stimulated macrophages after DHA treatment [44–46]. A
decrease in p65 expression could affect the formation and
activity of alternate dimers that could have different effects
on the TNFα compared to the IL-6 promotor. It is also
possible that the selective effect of DHA on TNFα compared
to IL-6 secretion are NFκB independent.
Since nuclear receptors such as PPARs are known to
repress NFκB activity by a process called ligand dependent
transrepression (Ref. [14] for review), we examined whether
levels of PPAR, RXR, and LXR were decreased in CF
macrophages. At baseline, mRNA expression of PPARγ was
significantly lower in CF macrophages. This is in agreement
with our previous study of PPARγ expression in CFTR
regulated tissues from cftr−/− mice [47]. After LPS
stimulation there was a blunted response in the expression
of PPARδ, LXRα and RXRα and the LXR target gene
ABCA1 in CF macrophages. These results suggest that the
formation of functional PPAR/RXR heterodimers is im-
paired in CF macrophages both at baseline and after LPSstimulation. Defective PPAR activity was confirmed by
EMSAwhere there was defective binding to the PPRE in CF
macrophages. Since all isoforms of PPAR as wells as LXR
have been shown to downregulate LPS induced cytokine
secretion [18,48,49] and LXR expression in macrophages
has been shown to be essential in the defense against bac-
terial infection [25], the impaired expression of these factors
in CF macrophages would potentially lead to a proinflam-
matory state.
The expression of nuclear transcription factors in bone
marrow derived macrophages after LPS and interferon-γ
stimulation was recently characterized by Barish et al. [35].
They found that activation of macrophages initiated a
complex serial expression pattern of nuclear receptors that
involved early, intermediate and late responses. Our results
on LPS induced expression of transcription factors in WT
peritoneal macrophages described in the current study are in
general agreement with those by Barish et al. While PPARα
expression was not altered by LPS, PPARγ decreased to 3%
of basal levels, within 8 h of LPS exposure which is
consistent with Barish's study. The increase in PPARδ
peaked at 8 h after LPS exposure while in the study by Barish
et al. it peaked at 16 h. LXRα expression peaked at 16 h in
both studies. RXR was not altered after LPS stimulation in
this study, which differs from the Barish study where RXR
was a late marker that increased by 24 h. The differences
observed between the studies may depend on the different
populations of macrophages (bone marrow vs. peritoneal
macrophages) or the fact that Barish et al. used a 10 fold
higher concentration of LPS.
These results provided an opportunity to determine
whether the mechanism of action of DHA is through
activation of PPAR/RXR/LXR nuclear transcription factors.
We have previously shown that high doses of oral DHA leads
to reversal of the CF phenotype in pancreas and ileum, as well
as attenuation of LPS induced lung inflammation in cftr−/−
mice [11]. In the current study, DHA treatment (in vivo or in
vitro) decreased TNFα secretion in CF macrophages. This
was associated with a decrease in p65 NFκB activity. Having
shown that PPAR/LXR pathways are dysfunctional in CF
macrophages we examined the effect of DHA on these
pathways. DHA is a well known PPARα ligand and EMSA
analysis showed that PPARα is significantly increased in CF
macrophages after oral DHA treatment. By RT-PCR, DHA
increased expression of PPARα, PPARγ and RXRα in CF
but not in WT macrophages. The expressions of the PPARα
target gene Acyl CoA-oxidase [50,51] and the PPARγ target
gene CD36 [52,53] were also increased selectively in CF
macrophages. There was no effect of DHA on PPARδ, or
LXRα or its downstream product ABCA1.
Furthermore we showed that the effect of DHA on LPS
induced TNFα secretion can be reproduced by PPARα
(Wy14643) and PPARγ (Roziglitazone) agonists. Although
PPARγ agonists has been demonstrated by several groups to
have PPARγ independent effects, the effect of rosiglitazone
on TNFα secretion has been shown to be PPARγ dependent
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DHA on TNFα secretion indicating that DHA acts through
PPARα. DHA was the only n-3 fatty acid tested that
decreased TNFα secretion significantly although there was a
trend for the same effect using EPA. Interestingly the n-6
fatty acid linoleic acid decreased TNFα secretion in CF
macrophages, but not in WT.
CF patients [12] as well as cftr−/− mice [11] have low
levels of linoleic acid and DHA. Since fatty acids are ligands
to PPARs, alterations in the fatty acid profile of CF
macrophages could provide an explanation for the decreased
PPAR activity. However, no reduction in DHA levels was
seen in CF macrophages compared to WT. Hence, low DHA
levels are not the explanation as to why PPARs are
dysfunctional in CF peritoneal macrophages. Interestingly,
the end product of the n-6 fatty acid pathway, 22:5, was
increased in CF macrophages which could suggest increased
metabolism in the n-6 fatty acid pathway.
Despite normal levels of DHA in CF peritoneal macro-
phages, DHA administration in vivo was still able to increase
PPAR activity and induce an anti-inflammatory effect
suggesting that DHA mediates its effects in part through
PPAR activation. However, DHA may have other anti-
inflammatory properties including lowering of arachidonic
acid levels as well as providing the substrate for the production
of resolvins and docosatrienes which are important for the
termination of the inflammatory process [55–58].
In summary, our results suggest that defective regulation
of proinflammatory pathways due to impaired PPAR and
LXR expression and function in macrophages may be a
contributing factor to the excessive inflammation in CF. DHA
treatment increased PPAR activity, decreased NF-κB activity,
and decreased TNFα secretion from CF macrophages. These
data suggest that DHA acts, at least in part, through PPARα
and γ in macrophages to reduce CF associated inflammation
and that this may provide a potential therapeutic pathway for
treatment of CF.
References
[1] Vandivier RW, Henson PM, Douglas IS. Burying the dead: the impact
of failed apoptotic cell removal (efferocytosis) on chronic inflamma-
tory lung disease. Chest 2006;129:1673–82.
[2] Tirouvanziam R, de Bentzmann S, Hubeau C, Hinnrasky J, Jacquot
J, Peault B, et al. Inflammation and infection in naive human
cystic fibrosis airway grafts. Am J Respir Cell Mol Biol 2000;23:
121–7.
[3] Zahm JM, Gaillard D, Dupuit F, Hinnrasky J, Porteous D, Dorin JR,
et al. Early alterations in airway mucociliary clearance and inflam-
mation of the lamina propria in CF mice. Am J Physiol 1997;272:
C853–9.
[4] Xu Y, Clark JC, Aronow BJ, Dey CR, Liu C, Wooldridge JL, et al.
Transcriptional adaptation to cystic fibrosis transmembrane conduc-
tance regulator deficiency. J Biol Chem 2003;278:7674–82.
[5] Bonfield TL, Panuska JR, Konstan MW, Hilliard KA, Hilliard JB,
Ghnaim H, et al. Inflammatory cytokines in cystic fibrosis lungs. Am J
Respir Crit Care Med 1995;152:2111–8.
[6] Moss RB. Lymphocytes in cystic fibrosis lung disease: a tale of two
immunities. Clin Exp Immunol 2004;135:358–60.[7] ZamanMM,GelrudA, Junaidi O, ReganMM,WarnyM, Shea JC, et al.
Interleukin 8 secretion frommonocytes of subjects heterozygous for the
deltaF508 cystic fibrosis transmembrane conductance regulator gene
mutation is altered. Clin Diagn Lab Immunol 2004;11:819–24.
[8] Thomas GR, Costelloe EA, Lunn DP, Stacey KJ, Delaney SJ, Passey
R, et al. G551D cystic fibrosis mice exhibit abnormal regulation of
inflammation in lungs and macrophages. J Immunol 2000;164:3870–7.
[9] Freedman SD, Weinstein D, Blanco PG, Martinez-Clark P, Urman S,
Zaman M, et al. Characterization of LPS-induced lung inflammation in
cftr−/− mice and the effect of docosahexaenoic acid. J Appl Physiol
2002;92:2169–76.
[10] Heeckeren A, Walenga R, Konstan MW, Bonfield T, Davis PB, Ferkol
T. Excessive inflammatory response of cystic fibrosis mice to
bronchopulmonary infection with Pseudomonas aeruginosa. J Clin
Invest 1997;100:2810–5.
[11] Freedman SD, Katz MH, Parker EM, Laposata M, UrmanMY, Alvarez
JG. A membrane lipid imbalance plays a role in the phenotypic
expression of cystic fibrosis in cftr(−/−) mice. Proc Natl Acad Sci U S A
1999;96:13995–4000.
[12] Freedman SD, Blanco PG, Zaman MM, Shea JC, Ollero M, Hopper
IK, et al. Association of cystic fibrosis with abnormalities in fatty acid
metabolism. N Engl J Med 2004;350:560–9.
[13] Blanco PG, ZamanMM, Junaidi O, Sheth S, Yantiss RK,Nasser IA, et al.
Induction of colitis in cftr−/−mice results in bile duct injury. Am J Physiol
Gastrointest Liver Physiol 2004;287:G491–6.
[14] Glass CK, Ogawa S. Combinatorial roles of nuclear receptors in
inflammation and immunity. Nat Rev Immunol 2006;6:44–55.
[15] Cuzzocrea S, Mazzon E, Di Paola R, Peli A, Bonato A, Britti D, et al.
The role of the peroxisome proliferator-activated receptor-alpha
(PPAR-alpha) in the regulation of acute inflammation. J Leukoc Biol
2006;79:999–1010.
[16] Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of
monocyte inflammatory cytokines. Nature 1998;391:82–6.
[17] Wang AC, Dai X, Luu B, Conrad DJ. Peroxisome proliferator-
activated receptor-gamma regulates airway epithelial cell activation.
Am J Respir Cell Mol Biol 2001;24:688–93.
[18] Joseph SB, Castrillo A, Laffitte BA, Mangelsdorf DJ, Tontonoz P.
Reciprocal regulation of inflammation and lipid metabolism by liver X
receptors. Nat Med 2003;9:213–9.
[19] Cunard R,RicoteM,DiCampli D, ArcherDC, KahnDA,Glass CK, et al.
Regulation of cytokine expression by ligands of peroxisome proliferator
activated receptors. J Immunol 2002;168:2795–802.
[20] Chinetti G, Griglio S, Antonucci M, Torra IP, Delerive P, Majd Z, et al.
Activation of proliferator-activated receptors alpha and gamma induces
apoptosis of human monocyte-derived macrophages. J Biol Chem
1998;273:25573–80.
[21] Padilla J, Leung E, Phipps RP. Human B lymphocytes and B lymphomas
express PPAR-gamma and are killed by PPAR-gamma agonists. Clin
Immunol 2002;103:22–33.
[22] Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome
proliferator-activated receptor-gamma is a negative regulator of
macrophage activation. Nature 1998;391:79–82.
[23] Woerly G, Honda K, Loyens M, Papin JP, Auwerx J, Staels B, et al.
Peroxisome proliferator-activated receptors alpha and gamma down-
regulate allergic inflammation and eosinophil activation. J Exp Med
2003;198:411–21.
[24] Asada K, Sasaki S, Suda T, Chida K, Nakamura H. Antiinflammatory
roles of peroxisome proliferator-activated receptor gamma in human
alveolar macrophages. Am J Respir Crit Care Med 2004;169:195–200.
[25] Joseph SB, Bradley MN, Castrillo A, Bruhn KW, Mak PA, Pei L, et al.
LXR-dependent gene expression is important for macrophage survival
and the innate immune response. Cell 2004;119:299–309.
[26] Devchand PR, Keller H, Peters JM, Vazquez M, Gonzalez FJ, Wahli
W. The PPARalpha-leukotriene B4 pathway to inflammation control.
Nature 1996;384:39–43.
[27] Auboeuf D, Rieusset J, Fajas L, Vallier P, Frering V, Riou JP, et al.
Tissue distribution and quantification of the expression of mRNAs of
78 C. Andersson et al. / Journal of Cystic Fibrosis 7 (2008) 68–78peroxisome proliferator-activated receptors and liver X receptor-alpha
in humans: no alteration in adipose tissue of obese and NIDDM
patients. Diabetes 1997;46:1319–27.
[28] Svensson PA, Hagg DA, Jernas M, Englund MC, Hulten LM, Ohlsson
BG, et al. Identification of genes predominantly expressed in human
macrophages. Atherosclerosis 2004;177:287–90.
[29] Repa JJ, Mangelsdorf DJ. The role of orphan nuclear receptors in the
regulation of cholesterol homeostasis. Annu Rev Cell Dev Biol 2000;16:
459–81.
[30] Zhang Y, Beyer TP, Bramlett KS, Yao S, Burris TP, Schmidt RJ, et al.
Liver X receptor and retinoic X receptor mediated ABCA1 regulation
and cholesterol efflux in macrophage cells-messenger RNA measured
by branched DNA technology. Mol Genet Metab 2002;77:150–8.
[31] Janowski BA, Willy PJ, Devi TR, Falck JR, Mangelsdorf DJ. An
oxysterol signalling pathway mediated by the nuclear receptor LXR
alpha. Nature 1996;383:728–31.
[32] Lehmann JM, Kliewer SA, Moore LB, Smith-Oliver TA, Oliver BB,
Su JL, et al. Activation of the nuclear receptor LXR by oxysterols
defines a new hormone response pathway. J Biol Chem 1997;272:
3137–40.
[33] Yoshikawa T, Shimano H, Yahagi N, Ide T, Amemiya-Kudo M,
Matsuzaka T, et al. Polyunsaturated fatty acids suppress sterol
regulatory element-binding protein 1c promoter activity by inhibition
of liver X receptor (LXR) binding to LXR response elements. J Biol
Chem 2002;277:1705–11.
[34] Tobin KA, Steineger HH, Alberti S, Spydevold O, Auwerx J, Gustafsson
JA, et al. Cross-talk between fatty acid and cholesterol metabolism
mediated by liver X receptor-alpha. Mol Endocrinol 2000;14:741–52.
[35] Barish GD, Downes M, Alaynick WA, Yu RT, Ocampo CB, Bookout
AL, et al. A nuclear receptor atlas: macrophage activation. Mol
Endocrinol 2005;19:2466–77.
[36] Kehrer JP, Biswal SS, La E, Thuillier P, Datta K, Fischer SM, et al.
Inhibition of peroxisome-proliferator-activated receptor (PPAR)alpha
by MK886. Biochem J 2001;356:899–906.
[37] Pfeffer KD, Huecksteadt TP, Hoidal JR. Expression and regulation of
tumor necrosis factor in macrophages from cystic fibrosis patients. Am
J Respir Cell Mol Biol 1993;9:511–9.
[38] Yoshimura K, Nakamura H, Trapnell BC, Chu CS, Dalemans W,
Pavirani A, et al. Expression of the cystic fibrosis transmembrane
conductance regulator gene in cells of non-epithelial origin. Nucleic
Acids Res 1991;19:5417–23.
[39] Muller JM, Ziegler-Heitbrock HW, Baeuerle PA. Nuclear factor kappa
B, a mediator of lipopolysaccharide effects. Immunobiology 1993;187:
233–56.
[40] Urban MB, Schreck R, Baeuerle PA. NF-kappa B contacts DNA by a
heterodimer of the p50 and p65 subunit. EMBO J 1991;10:1817–25.
[41] Liu H, Sidiropoulos P, Song G, Pagliari LJ, Birrer MJ, Stein B, et al.
TNF-alpha gene expression in macrophages: regulation by NF-kappa
B is independent of c-Jun or C/EBP beta. J Immunol 2000;164:
4277–85.
[42] Chen BC, Liao CC, Hsu MJ, Liao YT, Lin CC, Sheu JR, et al.
Peptidoglycan-induced IL-6 production in RAW 264.7 macrophages is
mediated by cyclooxygenase-2, PGE2/PGE4 receptors, protein kinase
A, I kappa B kinase, and NF-kappa B. J Immunol 2006;177:681–93.
[43] Joseph T, Look D, Ferkol T. NF-kappaB activation and sustained
IL-8 gene expression in primary cultures of cystic fibrosis airwayepithelial cells stimulated with Pseudomonas aeruginosa. Am J
Physiol Lung Cell Mol Physiol 2005;288:L471–9.
[44] Novak TE, Babcock TA, Jho DH, Helton WS, Espat NJ. NF-kappa B
inhibition by omega-3 fatty acids modulates LPS-stimulated macro-
phage TNF-alpha transcription. Am J Physiol Lung Cell Mol Physiol
2003;284:L84–9.
[45] Weldon SM, Mullen AC, Loscher CE, Hurley LA, Roche HM.
Docosahexaenoic acid induces an anti-inflammatory profile in
lipopolysaccharide-stimulated human THP-1 macrophages more
effectively than eicosapentaenoic acid. J Nutr Biochem 2007;18:
250–8.
[46] Zhao G, Etherton TD, Martin KR, Vanden Heuvel JP, Gillies PJ, West
SG, et al. Anti-inflammatory effects of polyunsaturated fatty acids in
THP-1 cells. Biochem Biophys Res Commun 2005;336:909–17.
[47] Ollero M, Junaidi O, Zaman MM, Tzameli I, Ferrando AA, Andersson
C, et al. Decreased expression of peroxisome proliferator activated
receptor gamma in cftr−/−mice. J Cell Physiol 2004;200:235–44.
[48] Kostadinova R, Wahli W, Michalik L. PPARs in diseases: control
mechanisms of inflammation. Curr Med Chem 2005;12:2995–3009.
[49] Ding G, Cheng L, Qin Q, Frontin S, Yang Q. PPARdelta modulates
lipopolysaccharide-induced TNFalpha inflammation signaling in
cultured cardiomyocytes. J Mol Cell Cardiol 2006.
[50] Hsu MH, Savas U, Griffin KJ, Johnson EF. Identification of
peroxisome proliferator-responsive human genes by elevated expres-
sion of the peroxisome proliferator-activated receptor alpha in HepG2
cells. J Biol Chem 2001;276:27950–8.
[51] Varanasi U, Chu R, Huang Q, Castellon R, Yeldandi AV, Reddy JK.
Identification of a peroxisome proliferator-responsive element up-
stream of the human peroxisomal fatty acyl coenzyme A oxidase gene.
J Biol Chem 1996;271:2147–55.
[52] Tontonoz P, Nagy L, Alvarez JG, Thomazy VA, Evans RM.
PPARgamma promotes monocyte/macrophage differentiation and
uptake of oxidized LDL. Cell 1998;93:241–52.
[53] Munteanu A, Taddei M, Tamburini I, Bergamini E, Azzi A, Zingg JM.
Antagonistic effects of oxidized low density lipoprotein and alpha-
tocopherol on CD36 scavenger receptor expression in monocytes:
involvement of protein kinase B and peroxisome proliferator-activated
receptor-gamma. J Biol Chem 2006;281:6489–97.
[54] Hong G, Davis B, Khatoon N, Baker SF, Brown J. PPAR gamma-
dependent anti-inflammatory action of rosiglitazone in human
monocytes: suppression of TNF alpha secretion is not mediated by
PTEN regulation. Biochem Biophys Res Commun 2003;303:782–7.
[55] Hong S, Gronert K, Devchand PR, Moussignac RL, Serhan CN. Novel
docosatrienes and 17S-resolvins generated from docosahexaenoic acid
in murine brain, human blood, and glial cells. Autacoids in anti-
inflammation. J Biol Chem 2003;278:14677–87.
[56] Marcheselli VL,Hong S, LukiwWJ, TianXH, Gronert K,Musto A, et al.
Novel docosanoids inhibit brain ischemia-reperfusion-mediated leuko-
cyte infiltration and pro-inflammatory gene expression. J Biol Chem
2003;278:43807–17.
[57] Serhan CN. Novel omega-3-derived local mediators in anti-inflamma-
tion and resolution. Pharmacol Ther 2005;105:7–21.
[58] Serhan CN, Hong S, Gronert K, Colgan SP, Devchand PR, Mirick G.
Resolvins: a family of bioactive products of omega-3 fatty acid
transformation circuits initiated by aspirin treatment that counter
proinflammation signals. J Exp Med 2002;196:1025–37.
